Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Ann Neurol
    October 2021
  1. SANDROCK A
    Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.
    Ann Neurol. 2021 Oct 23. doi: 10.1002/ana.26254.
    >> Share

  2. DAS SR, Lyu X, Duong MT, Xie L, et al
    Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease.
    Ann Neurol. 2021 Oct 7. doi: 10.1002/ana.26233.
    >> Share

    September 2021
  3. PETERSEN RC
    Aducanumab: What about the Patient?
    Ann Neurol. 2021;90:334-335.
    >> Share

    July 2021
  4. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    >> Share

  5. MONTAL V, Barroeta I, Bejanin A, Pegueroles J, et al
    Metabolite signature of Alzheimer's disease in adults with Down syndrome.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26178.
    >> Share

  6. DAUTRICOURT S, de Flores R, Landeau B, Poisnel G, et al
    Longitudinal changes in hippocampal network connectivity in Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26168.
    >> Share

  7. MOGHAVEM N, Henderson VW, Greicius MD
    Medicare should not cover aducanumab as a treatment for Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26167.
    >> Share

    May 2021
  8. LIN BSZ, Sur S, Liu P, Li Y, et al
    Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26134.
    >> Share

  9. SARIYA S, Felsky D, Reyes-Dumeyer D, Lali R, et al
    Polygenic risk score for Alzheimer's Disease in Caribbean Hispanics.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26131.
    >> Share

    April 2021
  10. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    March 2021
  11. PETERSEN RC, Wiste HJ, Weigand SD, Fields JA, et al
    NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26071.
    >> Share

  12. BUCIUC M, Whitwell JL, Kasanuki K, Graff-Radford J, et al
    Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.
    Ann Neurol. 2021;89:520-533.
    >> Share

    February 2021
  13. KONIJNENBERG E, Tomassen J, den Braber A, Ten Kate M, et al
    The onset of preclinical Alzheimer's disease in monozygotic twins.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26048.
    >> Share

  14. FILIPPONE A, Pratico D
    Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer's disease pathology.
    Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26042.
    >> Share

  15. MEEKER KL, Wisch JK, Hudson D, Coble D, et al
    Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.
    Ann Neurol. 2021;89:254-265.
    >> Share

    December 2020
  16. RAJAN KB, Aggarwal NT, McAninch EA, Weuve J, et al
    Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Ann Neurol. 2020;88:1065-1076.
    >> Share

    November 2020
  17. LESMAN-SEGEV OH, La Joie R, Iaccarino L, Lobach I, et al
    Diagnostic Accuracy of Amyloid versus FDG PET in Autopsy-Confirmed Dementia.
    Ann Neurol. 2020 Nov 20. doi: 10.1002/ana.25968.
    >> Share

  18. BUCKLEY RF, Scott MR, Jacobs HIL, Schultz AP, et al
    Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.
    Ann Neurol. 2020;88:921-932.
    >> Share

    October 2020
  19. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25947.
    >> Share

  20. MOUSSA C
    Reply to Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25946.
    >> Share

  21. NOYCE AJ, Klein C
    Genetic risk of Alzheimer's disease - Sleepless with the enemy.
    Ann Neurol. 2020 Oct 18. doi: 10.1002/ana.25938.
    >> Share

  22. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    >> Share

    September 2020
  23. ANDREWS SJ, Fulton-Howard B, O'Reilly P, Marcora E, et al
    Causal associations between modifiable risk factors and the Alzheimer's phenome.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25918.
    >> Share

  24. LENG Y, Ackley SF, Glymour MM, Yaffe K, et al
    Genetic risk of Alzheimer's disease and sleep duration in non-demented elders.
    Ann Neurol. 2020 Sep 20. doi: 10.1002/ana.25910.
    >> Share

  25. LAO PJ, Gutierrez J, Keator D, Rizvi B, et al
    Alzheimer's-related cerebrovascular disease in Down syndrome.
    Ann Neurol. 2020 Sep 18. doi: 10.1002/ana.25905.
    >> Share

    August 2020
  26. GHIRELLI A, Tosakulwong N, Weigand SD, Clark HM, et al
    Sensitivity-specificity of tau and Abeta PET in frontotemporal lobar degeneration.
    Ann Neurol. 2020 Aug 31. doi: 10.1002/ana.25893.
    >> Share

  27. MENGEL D, Janelidze S, Glynn RJ, Liu W, et al
    Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
    Ann Neurol. 2020 Aug 23. doi: 10.1002/ana.25885.
    >> Share

  28. HALPERIN JJ, Pascual-Leone A, Saper CB
    Symptomatic Hydrocephalus with Normal Cerebrospinal Pressure and Alzheimer's Disease.
    Ann Neurol. 2020 Aug 9. doi: 10.1002/ana.25871.
    >> Share

    July 2020
  29. MULLER-SCHMITZ K, Krasavina-Loka N, Yardimci T, Lipka T, et al
    Normal pressure hydrocephalus associated with Alzheimer' disease.
    Ann Neurol. 2020 Jul 13. doi: 10.1002/ana.25847.
    >> Share

  30. NUNEZ C, Callen A, Lombardini F, Compta Y, et al
    Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance.
    Ann Neurol. 2020;88:67-80.
    >> Share

    June 2020
  31. ARVANITAKIS Z, Wang HY, Capuano AW, Khan A, et al
    Brain insulin signaling, Alzheimer's disease pathology, and cognitive function.
    Ann Neurol. 2020 Jun 18. doi: 10.1002/ana.25826.
    >> Share

  32. IRWIN DJ, Felder J, Coffey CS, Caspell-Garcia C, et al
    Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Ann Neurol. 2020 Jun 16. doi: 10.1002/ana.25811.
    >> Share

  33. SCARIONI M, Gami-Patel P, Timar Y, Seelaar H, et al
    Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology.
    Ann Neurol. 2020;87:950-961.
    >> Share

  34. BUCKLEY R, Pascual-Leone A
    Age-Related Cognitive Decline Is Indicative of Neuropathology.
    Ann Neurol. 2020;87:813-815.
    >> Share

    May 2020
  35. TURNER RS, Hebron ML, Lawler A, Mundel EE, et al
    Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
    Ann Neurol. 2020 May 28. doi: 10.1002/ana.25775.
    >> Share

  36. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    >> Share

    April 2020
  37. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    >> Share

    March 2020
  38. STRANDBERG TE, Tienari PJ, Kivimaki M
    Vascular and Alzheimer's disease in dementia.
    Ann Neurol. 2020 Mar 10. doi: 10.1002/ana.25715.
    >> Share

    January 2020
  39. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    >> Share

  40. DESPA F, Goldstein LB, Biessels GJ
    Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease.
    Ann Neurol. 2020 Jan 9. doi: 10.1002/ana.25668.
    >> Share

    November 2019
  41. HANSEEUW BJ, Scott MR, Sikkes S, Properzi M, et al
    Evolution of anosognosia in Alzheimer's disease and its relationship to amyloid.
    Ann Neurol. 2019 Nov 21. doi: 10.1002/ana.25649.
    >> Share

  42. GUSTAVSSON AM, van Westen D, Stomrud E, Engstrom G, et al
    Midlife atherosclerosis and development of Alzheimer's or vascular dementia.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25645.
    >> Share

  43. WILLIAMS DM, Finan C, Schmidt AF, Burgess S, et al
    Lipid lowering and Alzheimer's disease risk: a Mendelian randomization study.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25642.
    >> Share

  44. PRINS S, Zhuparris A, Groeneveld GJ
    The Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes depends on the study population.
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25634.
    >> Share

  45. VERBERK IMW, Teunissen CE, Van der Flier WM
    Reply to "The Usefulness of Plasma Amyloid as Prescreener of the earliest Alzheimer Pathological Changes depends on the study population".
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25633.
    >> Share

    October 2019
  46. JAMES BD, Wilson RS, Capuano AW, Boyle PA, et al
    Hospitalization, Alzheimer's and Related Neuropathologies, and Cognitive Decline.
    Ann Neurol. 2019 Oct 15. doi: 10.1002/ana.25621.
    >> Share

    September 2019
  47. MENG Y, Abrahao A, Heyn CC, Bethune AJ, et al
    Glymphatics visualization after focused ultrasound induced blood-brain barrier opening in humans.
    Ann Neurol. 2019 Sep 16. doi: 10.1002/ana.25604.
    >> Share

    August 2019
  48. KUMMER BR, Diaz I, Wu X, Aaroe AE, et al
    Associations between cerebrovascular risk factors and parkinson disease.
    Ann Neurol. 2019 Aug 29. doi: 10.1002/ana.25564.
    >> Share

    July 2019
  49. SCHULTZ A, Kloet RW, Sohrabi HR, van der Weerd L, et al
    Amyloid Imaging of Dutch-type Hereditary Cerebral Amyloid Angiopathy Carriers.
    Ann Neurol. 2019 Jul 30. doi: 10.1002/ana.25560.
    >> Share

    February 2019
  50. COUGHLIN D, Xie SX, Liang M, Williams A, et al
    Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Ann Neurol. 2019;85:259-271.
    >> Share

    January 2019
  51. GABELLE A, Jaussent I, Bouallegue FB, Lehmann S, et al
    Reduced brain amyloid burden in elderly patients with narcolepsy type 1.
    Ann Neurol. 2019;85:74-83.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016